Editing Botulinum toxin (section)

===Chronic migraine===
{{See also|Migraine treatment#Botulinum Toxin (Botox)}}

Onabotulinumtoxin A (trade name: Botox) received FDA approval for treatment of chronic [[migraine]]s on 15 October 2010. The toxin is injected into the head and neck to treat these chronic headaches. Approval followed evidence presented to the agency from two studies funded by Allergan showing a very slight improvement in incidence of chronic migraines for those with migraines undergoing the Botox treatment.<ref name=FDA10>{{cite press release |title=FDA approves Botox to treat chronic migraine |publisher=U.S. [[Food and Drug Administration]] (FDA) |date=19 October 2010 |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm |archive-url=https://web.archive.org/web/20101019002022/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm |archive-date=19 October 2010 |url-status=dead |access-date=23 November 2019}} {{PD-notice}}</ref><ref>{{Cite news |vauthors=Watkins T |date=15 October 2010 |title=FDA approves Botox as migraine preventative |newspaper=[[CNN]] |url=http://us.cnn.com/2010/HEALTH/10/15/migraines.botox/index.html |access-date=16 October 2010 |archive-date=27 July 2020 |archive-url=https://web.archive.org/web/20200727025543/http://us.cnn.com/2010/HEALTH/10/15/migraines.botox/index.html |url-status=live }}</ref>

Since then, several randomized control trials have shown botulinum toxin type A to improve headache symptoms and quality of life when used prophylactically for participants with chronic [[migraine]]<ref>{{cite journal |vauthors = Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF |title = OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program |journal = Headache |volume = 50 |issue = 6 |pages = 921–936 |date = June 2010 |pmid = 20487038 |doi = 10.1111/j.1526-4610.2010.01678.x |s2cid = 9621285 }}</ref> who exhibit headache characteristics consistent with: pressure perceived from outside source, shorter total duration of chronic migraines (<30 years), "detoxification" of participants with coexisting chronic daily headache due to medication overuse, and no current history of other preventive headache medications.<ref>{{cite journal |vauthors = Ashkenazi A |title = Botulinum toxin type a for chronic migraine |journal = Current Neurology and Neuroscience Reports |volume = 10 |issue = 2 |pages = 140–146 |date = March 2010 |pmid = 20425239 |doi = 10.1007/s11910-010-0087-5 |s2cid = 32191932 }}</ref>